 | • レポートコード：GIR-105X08409 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、肝性脳症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。肝性脳症治療薬の種類別市場規模（注射、経口）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・肝性脳症治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：ASKA Pharmaceutical、Cosmo Pharmaceuticals、Bausch Health、Ferring Pharmaceuticals、Mallinckrodt、Umecrine Cognition、Norgine、Lupin、Kaleido Biosciences、Kannalife Sciences ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：注射、経口 ・用途別分析2016年-2026年：病院薬局、小売薬局、オンライン薬局 ・肝性脳症治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・肝性脳症治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・肝性脳症治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・肝性脳症治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・肝性脳症治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Hepatic Encephalopathy Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Hepatic Encephalopathy Drugs size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Hepatic Encephalopathy Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Hepatic Encephalopathy Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Injection
Oral
Market segment by Application can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The key market players for global Hepatic Encephalopathy Drugs market are listed below:
ASKA Pharmaceutical
Cosmo Pharmaceuticals
Bausch Health
Ferring Pharmaceuticals
Mallinckrodt
Umecrine Cognition
Norgine
Lupin
Kaleido Biosciences
Kannalife Sciences
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Hepatic Encephalopathy Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hepatic Encephalopathy Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Injection
1.2.3 Oral
1.3 Market Analysis by Application
1.3.1 Overview: Global Hepatic Encephalopathy Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Hepatic Encephalopathy Drugs Market Size & Forecast
1.4.1 Global Hepatic Encephalopathy Drugs Sales in Value (2016-2026))
1.4.2 Global Hepatic Encephalopathy Drugs Sales in Volume (2016-2026)
1.4.3 Global Hepatic Encephalopathy Drugs Price by Type (2016-2026) & (USD/Kg)
1.5 Global Hepatic Encephalopathy Drugs Production Capacity Analysis
1.5.1 Global Hepatic Encephalopathy Drugs Total Production Capacity (2016-2026)
1.5.2 Global Hepatic Encephalopathy Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hepatic Encephalopathy Drugs Market Drivers
1.6.2 Hepatic Encephalopathy Drugs Market Restraints
1.6.3 Hepatic Encephalopathy Drugs Trends Analysis
2 Manufacturers Profiles
2.1 ASKA Pharmaceutical
2.1.1 ASKA Pharmaceutical Details
2.1.2 ASKA Pharmaceutical Major Business
2.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product and Services
2.1.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Cosmo Pharmaceuticals
2.2.1 Cosmo Pharmaceuticals Details
2.2.2 Cosmo Pharmaceuticals Major Business
2.2.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product and Services
2.2.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Bausch Health
2.3.1 Bausch Health Details
2.3.2 Bausch Health Major Business
2.3.3 Bausch Health Hepatic Encephalopathy Drugs Product and Services
2.3.4 Bausch Health Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Ferring Pharmaceuticals
2.4.1 Ferring Pharmaceuticals Details
2.4.2 Ferring Pharmaceuticals Major Business
2.4.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product and Services
2.4.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Mallinckrodt
2.5.1 Mallinckrodt Details
2.5.2 Mallinckrodt Major Business
2.5.3 Mallinckrodt Hepatic Encephalopathy Drugs Product and Services
2.5.4 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Umecrine Cognition
2.6.1 Umecrine Cognition Details
2.6.2 Umecrine Cognition Major Business
2.6.3 Umecrine Cognition Hepatic Encephalopathy Drugs Product and Services
2.6.4 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Norgine
2.7.1 Norgine Details
2.7.2 Norgine Major Business
2.7.3 Norgine Hepatic Encephalopathy Drugs Product and Services
2.7.4 Norgine Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Lupin
2.8.1 Lupin Details
2.8.2 Lupin Major Business
2.8.3 Lupin Hepatic Encephalopathy Drugs Product and Services
2.8.4 Lupin Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.9 Kaleido Biosciences
2.9.1 Kaleido Biosciences Details
2.9.2 Kaleido Biosciences Major Business
2.9.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Product and Services
2.9.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.10 Kannalife Sciences
2.10.1 Kannalife Sciences Details
2.10.2 Kannalife Sciences Major Business
2.10.3 Kannalife Sciences Hepatic Encephalopathy Drugs Product and Services
2.10.4 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Hepatic Encephalopathy Drugs Sales by Manufacturer
3.1 Global Hepatic Encephalopathy Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Hepatic Encephalopathy Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Hepatic Encephalopathy Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Hepatic Encephalopathy Drugs Manufacturer Market Share
3.4.2 Top 6 Hepatic Encephalopathy Drugs Manufacturer Market Share
3.5 Global Hepatic Encephalopathy Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Hepatic Encephalopathy Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Hepatic Encephalopathy Drugs Market Size by Region
4.1.1 Global Hepatic Encephalopathy Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Hepatic Encephalopathy Drugs Revenue by Region (2016-2026)
4.2 North America Hepatic Encephalopathy Drugs Revenue (2016-2026)
4.3 Europe Hepatic Encephalopathy Drugs Revenue (2016-2026)
4.4 Asia-Pacific Hepatic Encephalopathy Drugs Revenue (2016-2026)
4.5 South America Hepatic Encephalopathy Drugs Revenue (2016-2026)
4.6 Middle East and Africa Hepatic Encephalopathy Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Hepatic Encephalopathy Drugs Sales in Volume by Type (2016-2026)
5.2 Global Hepatic Encephalopathy Drugs Revenue by Type (2016-2026)
5.3 Global Hepatic Encephalopathy Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Hepatic Encephalopathy Drugs Sales in Volume by Application (2016-2026)
6.2 Global Hepatic Encephalopathy Drugs Revenue by Application (2016-2026)
6.3 Global Hepatic Encephalopathy Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Hepatic Encephalopathy Drugs Sales by Type (2016-2026)
7.2 North America Hepatic Encephalopathy Drugs Sales by Application (2016-2026)
7.3 North America Hepatic Encephalopathy Drugs Market Size by Country
7.3.1 North America Hepatic Encephalopathy Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Hepatic Encephalopathy Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Hepatic Encephalopathy Drugs Sales by Type (2016-2026)
8.2 Europe Hepatic Encephalopathy Drugs Sales by Application (2016-2026)
8.3 Europe Hepatic Encephalopathy Drugs Market Size by Country
8.3.1 Europe Hepatic Encephalopathy Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Hepatic Encephalopathy Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Hepatic Encephalopathy Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Hepatic Encephalopathy Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Hepatic Encephalopathy Drugs Market Size by Region
9.3.1 Asia-Pacific Hepatic Encephalopathy Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Hepatic Encephalopathy Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Hepatic Encephalopathy Drugs Sales by Type (2016-2026)
10.2 South America Hepatic Encephalopathy Drugs Sales by Application (2016-2026)
10.3 South America Hepatic Encephalopathy Drugs Market Size by Country
10.3.1 South America Hepatic Encephalopathy Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Hepatic Encephalopathy Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Hepatic Encephalopathy Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Hepatic Encephalopathy Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Hepatic Encephalopathy Drugs Market Size by Country
11.3.1 Middle East & Africa Hepatic Encephalopathy Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Hepatic Encephalopathy Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Hepatic Encephalopathy Drugs Typical Distributors
12.3 Hepatic Encephalopathy Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Hepatic Encephalopathy Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Hepatic Encephalopathy Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. ASKA Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 4. ASKA Pharmaceutical Major Business
Table 5. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product and Services
Table 6. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Cosmo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 8. Cosmo Pharmaceuticals Major Business
Table 9. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product and Services
Table 10. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Bausch Health Basic Information, Manufacturing Base and Competitors
Table 12. Bausch Health Major Business
Table 13. Bausch Health Hepatic Encephalopathy Drugs Product and Services
Table 14. Bausch Health Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Ferring Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Ferring Pharmaceuticals Major Business
Table 17. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product and Services
Table 18. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Mallinckrodt Basic Information, Manufacturing Base and Competitors
Table 20. Mallinckrodt Major Business
Table 21. Mallinckrodt Hepatic Encephalopathy Drugs Product and Services
Table 22. Mallinckrodt Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Umecrine Cognition Basic Information, Manufacturing Base and Competitors
Table 24. Umecrine Cognition Major Business
Table 25. Umecrine Cognition Hepatic Encephalopathy Drugs Product and Services
Table 26. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Norgine Basic Information, Manufacturing Base and Competitors
Table 28. Norgine Major Business
Table 29. Norgine Hepatic Encephalopathy Drugs Product and Services
Table 30. Norgine Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Lupin Basic Information, Manufacturing Base and Competitors
Table 32. Lupin Major Business
Table 33. Lupin Hepatic Encephalopathy Drugs Product and Services
Table 34. Lupin Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Kaleido Biosciences Basic Information, Manufacturing Base and Competitors
Table 36. Kaleido Biosciences Major Business
Table 37. Kaleido Biosciences Hepatic Encephalopathy Drugs Product and Services
Table 38. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Kannalife Sciences Basic Information, Manufacturing Base and Competitors
Table 40. Kannalife Sciences Major Business
Table 41. Kannalife Sciences Hepatic Encephalopathy Drugs Product and Services
Table 42. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (MT), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Hepatic Encephalopathy Drugs Sales by Manufacturer (2019-2021e) & (MT)
Table 44. Global Hepatic Encephalopathy Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Hepatic Encephalopathy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Hepatic Encephalopathy Drugs Production Capacity by Company, (MT): 2020 VS 2021
Table 47. Head Office and Hepatic Encephalopathy Drugs Production Site of Key Manufacturer
Table 48. Global Hepatic Encephalopathy Drugs Sales by Region (2016-2021e) & (MT)
Table 49. Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026) & (MT)
Table 50. Global Hepatic Encephalopathy Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 51. Global Hepatic Encephalopathy Drugs Revenue by Region (2021-2026) & (USD Million)
Table 52. Global Hepatic Encephalopathy Drugs Sales by Type (2016-2021e) & (MT)
Table 53. Global Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (MT)
Table 54. Global Hepatic Encephalopathy Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 55. Global Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (USD Million)
Table 56. Global Hepatic Encephalopathy Drugs Price by Type (2016-2021e) & (USD/Kg)
Table 57. Global Hepatic Encephalopathy Drugs Price by Type (2021-2026) & (USD/Kg)
Table 58. Global Hepatic Encephalopathy Drugs Sales by Application (2016-2021e) & (MT)
Table 59. Global Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (MT)
Table 60. Global Hepatic Encephalopathy Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 61. Global Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (USD Million)
Table 62. Global Hepatic Encephalopathy Drugs Price by Application (2016-2021e) & (USD/Kg)
Table 63. Global Hepatic Encephalopathy Drugs Price by Application (2021-2026) & (USD/Kg)
Table 64. North America Hepatic Encephalopathy Drugs Sales by Country (2016-2021e) & (MT)
Table 65. North America Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (MT)
Table 66. North America Hepatic Encephalopathy Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 67. North America Hepatic Encephalopathy Drugs Revenue by Country (2021-2026) & (USD Million)
Table 68. North America Hepatic Encephalopathy Drugs Sales by Type (2016-2021e) & (MT)
Table 69. North America Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (MT)
Table 70. North America Hepatic Encephalopathy Drugs Sales by Application (2016-2021e) & (MT)
Table 71. North America Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (MT)
Table 72. Europe Hepatic Encephalopathy Drugs Sales by Country (2016-2021e) & (MT)
Table 73. Europe Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (MT)
Table 74. Europe Hepatic Encephalopathy Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 75. Europe Hepatic Encephalopathy Drugs Revenue by Country (2021-2026) & (USD Million)
Table 76. Europe Hepatic Encephalopathy Drugs Sales by Type (2016-2021e) & (MT)
Table 77. Europe Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (MT)
Table 78. Europe Hepatic Encephalopathy Drugs Sales by Application (2016-2021e) & (MT)
Table 79. Europe Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (MT)
Table 80. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Region (2016-2021e) & (MT)
Table 81. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Region (2021-2026) & (MT)
Table 82. Asia-Pacific Hepatic Encephalopathy Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 83. Asia-Pacific Hepatic Encephalopathy Drugs Revenue by Region (2021-2026) & (USD Million)
Table 84. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Type (2016-2021e) & (MT)
Table 85. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (MT)
Table 86. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Application (2016-2021e) & (MT)
Table 87. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (MT)
Table 88. South America Hepatic Encephalopathy Drugs Sales by Country (2016-2021e) & (MT)
Table 89. South America Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (MT)
Table 90. South America Hepatic Encephalopathy Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 91. South America Hepatic Encephalopathy Drugs Revenue by Country (2021-2026) & (USD Million)
Table 92. South America Hepatic Encephalopathy Drugs Sales by Type (2016-2021e) & (MT)
Table 93. South America Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (MT)
Table 94. South America Hepatic Encephalopathy Drugs Sales by Application (2016-2021e) & (MT)
Table 95. South America Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (MT)
Table 96. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Country (2016-2021e) & (MT)
Table 97. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (MT)
Table 98. Middle East & Africa Hepatic Encephalopathy Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 99. Middle East & Africa Hepatic Encephalopathy Drugs Revenue by Country (2021-2026) & (USD Million)
Table 100. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Type (2016-2021e) & (MT)
Table 101. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (MT)
Table 102. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Application (2016-2021e) & (MT)
Table 103. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (MT)
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Hepatic Encephalopathy Drugs Typical Distributors
Table 107. Hepatic Encephalopathy Drugs Typical Customers
List of Figures
Figure 1. Hepatic Encephalopathy Drugs Picture
Figure 2. Global Hepatic Encephalopathy Drugs Sales Market Share by Type in 2020
Figure 3. Injection
Figure 4. Oral
Figure 5. Global Hepatic Encephalopathy Drugs Sales Market Share by Application in 2020
Figure 6. Hospital Pharmacies
Figure 7. Retail Pharmacies
Figure 8. Online Pharmacies
Figure 9. Global Hepatic Encephalopathy Drugs Market Size, (USD Million) & (MT): 2020 VS 2021 VS 2026
Figure 10. Global Hepatic Encephalopathy Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. United States Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 12. Canada Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Mexico Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Germany Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. France Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. United Kingdom Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Russia Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Italy Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. China Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Japan Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Korea Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. India Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Southeast Asia Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Australia Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Brazil Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Egypt Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Saudi Arabia Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. South Africa Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Turkey Hepatic Encephalopathy Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Global Hepatic Encephalopathy Drugs Sales (2016-2026) & (MT)
Figure 31. Global Hepatic Encephalopathy Drugs Production Capacity (2016-2026) & (MT)
Figure 32. Global Hepatic Encephalopathy Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 33. Hepatic Encephalopathy Drugs Market Drivers
Figure 34. Hepatic Encephalopathy Drugs Market Restraints
Figure 35. Hepatic Encephalopathy Drugs Market Trends
Figure 36. Global Hepatic Encephalopathy Drugs Sales Market Share by Manufacturer in 2020
Figure 37. Global Hepatic Encephalopathy Drugs Revenue Market Share by Manufacturer in 2020
Figure 38. Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 39. Top 3 Hepatic Encephalopathy Drugs Manufacturer (Revenue) Market Share in 2020
Figure 40. Top 6 Hepatic Encephalopathy Drugs Manufacturer (Revenue) Market Share in 2020
Figure 41. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2016-2026)
Figure 42. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2016-2026)
Figure 43. North America Hepatic Encephalopathy Drugs Revenue (2016-2026) & (USD Million)
Figure 44. Europe Hepatic Encephalopathy Drugs Revenue (2016-2026) & (USD Million)
Figure 45. Asia-Pacific Hepatic Encephalopathy Drugs Revenue (2016-2026) & (USD Million)
Figure 46. South America Hepatic Encephalopathy Drugs Revenue (2016-2026) & (USD Million)
Figure 47. Middle East & Africa Hepatic Encephalopathy Drugs Revenue (2016-2026) & (USD Million)
Figure 48. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2026)
Figure 49. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2016-2026)
Figure 50. Global Hepatic Encephalopathy Drugs Price by Type (2016-2026) & (USD/Kg)
Figure 51. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2026)
Figure 52. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2016-2026)
Figure 53. Global Hepatic Encephalopathy Drugs Price by Application (2016-2026) & (USD/Kg)
Figure 54. North America Hepatic Encephalopathy Drugs Sales Market Share by Country (2016-2026)
Figure 55. North America Hepatic Encephalopathy Drugs Revenue Market Share by Country (2016-2026)
Figure 56. North America Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2026)
Figure 57. North America Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2026)
Figure 58. Europe Hepatic Encephalopathy Drugs Sales Market Share by Country (2016-2026)
Figure 59. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Country (2016-2026)
Figure 60. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2026)
Figure 61. Europe Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share by Region (2016-2026)
Figure 63. Asia-Pacific Hepatic Encephalopathy Drugs Revenue Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2026)
Figure 66. South America Hepatic Encephalopathy Drugs Sales Market Share by Country (2016-2026)
Figure 67. South America Hepatic Encephalopathy Drugs Revenue Market Share by Country (2016-2026)
Figure 68. South America Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2026)
Figure 69. South America Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Hepatic Encephalopathy Drugs Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Hepatic Encephalopathy Drugs Revenue Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Hepatic Encephalopathy Drugs Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Hepatic Encephalopathy Drugs Sales Market Share by Application (2016-2026)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel
Figure 75. Methodology
Figure 76. Research Process and Data Source
肝性脳症（HE）治療薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood. Scope of the Report: This report focuses on the Hepatic Encephalopathy (HE) Therapeutics in global market, especially in North America, Europe and Asia-Pacific, Sout…- OTC外用薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Topical drugs are used for the application where body surfaces such as the skin or mucous membranes to treat ailments. OTC Topical drugs are epicutaneous medication that are applied in the skin directly. The large range of classes included in the topical drugs are creams, foams, gels, lotions and oi…
- 世界の変形性関節症治療薬市場 2021：企業別、地域別、種類・用途別 The Osteoarthritis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulation…
- 禁煙薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Smoking cessation (also known as quitting smoking or simply quitting) is the process of discontinuing tobacco smoking. Tobacco smoke contains nicotine, which is addictive. Nicotine withdrawal makes the process of quitting often very prolonged and difficult. Scope of the Report: This report focuses o…
- 世界の皮膚炎治療薬市場 2021：企業別、地域別、種類・用途別 The Dermatitis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, r…